NFATC4 and cardiac hypertrophy: In the present study, pyridostigmine may have suppressed the formation of Orai1/STIM1 complex, resulting in inhibition of the activation of the CaN/NFAT3/GATA4 signalling pathway and attenuation of cardiac hypertrophy.